Variable Sensitivity to the Glucocorticoid Activity of Cortisol in Patients with Primary Adrenal Insufficiency: Assessment with ACTH Profiles

Abstract

Our aim was to investigate the usefulness of circulating levels of adrenocorticotropic hormone (ACTH) and also salivary cortisol to monitor cortisone substitution in patients with Addison's disease. 13 patients with primary adrenal insufficiency (8 women and 5 men, age 44±11 years) received 12.5 mg cortisone acetate orally at 16:00 h and 25 mg at 07:00 h. Blood samples for cortisol and ACTH analysis were drawn every hour for 24 h, and also every half hour between 07:00 and 12:00 h. Samples for salivary cortisol were collected in parallel. Total ACTH levels showed large inter-individual variations and a diurnal rhythm with a nadir in the early evening at 19:00 (median 19 ng/l, range 2–434 ng/l) and high levels in the early morning, with a peak around 07:30 (median 844 ng/l, range 45–2 249 ng/l). Plasma cortisol concentrations showed 2 peaks distinct in time, but variable in height, 1–2 h after intake of cortisone. Plasma cortisol correlated significantly with ln(ACTH) at 17:00 h (r=–0.56), at 10:00 h (r=–0.51), and at 10.30 h (r=–0.57). When tested at different time points, ln(ACTH) at 10:00 to 12:00 h was negatively correlated with plasma cortisol between 08:30 and 12:00 h. Plasma cortisol was highly correlated to ln(salivary cortisol) most of the time points measured, but 30–60 min after intake of cortisone acetate the correlation disappeared. In conclusion, the large interindividual variation in ACTH levels most likely indicates varying sensitivity to cortisol with a need for individualized dosing schemes. Furthermore ACTH-determinations may be useful for dose titration of cortisol.

Key words

cortisol - cortisone - ACTH - adrenal insufficiency

References

• 1 Oelkers W, Diederich S, Bahr V. Diagnosis and therapy surveillance in Addison's disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone.  J Clin Endocrinol Metab. 1992;  75 259-264
• 2 Besser GM, Jeffcoate WJ. Endocrine and metabolic diseases. Adrenal diseases.  Br Med J. 1976;  1 448-451
• 3 Oelkers W. Adrenal insufficiency.  N Engl J Med. 1996;  335 1206-1212
• 4 Arlt W, Allolio B. Adrenal insufficiency.  Lancet. 2003;  361 1881-1893
• 5 Ten S, New M, Maclaren N. Clinical review 130: Addison's disease 2001.  J Clin Endocrinol Metab. 2001;  86 2909-2922
• 6 Debono M, Ross RJ, Newell-Price J. Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy.  Eur J Endocrinol. 2009;  160 719-729
• 7 Feek CM, Ratcliffe JG, Seth J, Gray CE, Toft AD, Irvine WJ. Patterns of plasma cortisol and ACTH concentrations in patients with Addison's disease treated with conventional corticosteroid replacement.  Clin Endocrinol (Oxf). 1981;  14 451-458
• 8 Laureti S, Falorni A, Santeusanio F. Improvement of treatment of primary adrenal insufficiency by administration of cortisone acetate in 3 daily doses.  J Endocrinol Invest. 2003;  26 1071-1075
• 9 Scott RS, Donald RA, Espiner EA. Plasma ACTH and cortisol profiles in Addisonian patients receiving conventional substitution therapy.  Clin Endocrinol (Oxf). 1978;  9 571-576
• 10 Lewis JG, Mopert B, Shand BI, Doogue MP, Soule SG, Frampton CM, Elder PA. Plasma variation of corticosteroid-binding globulin and sex hormone-binding globulin.  Horm Metab Res. 2006;  38 241-245
• 11 Rosner W. Plasma steroid-binding proteins.  Endocrinol Metab Clin North Am. 1991;  20 697-720
• 12 Holder G. Measurement of glucocorticoids in biological fluids.  Methods Mol Biol. 2006;  324 141-157
• 13 Hiramatsu R. Direct assay of cortisol in human saliva by solid phase radioimmunoassay and its clinical applications.  Clin Chim Acta. 1981;  117 239-249
• 14 Read GF, Walker RF, Wilson DW, Griffiths K. Steroid analysis in saliva for the assessment of endocrine function.  Ann N Y Acad Sci. 1990;  595 260-274
• 15 Holdaway IM. Suppression of plasma ACTH levels with corticosteroids in Addison's disease.  Clin Endocrinol (Oxf). 1973;  2 37-42
• 16 Baid SK, Rubino D, Sinaii N, Ramsey S, Frank A, Nieman LK. Specificity of screening tests for Cushing's syndrome in an overweight and obese population.  J Clin Endocrinol Metab. 2009;  94 3857-3864
• 17 Blomgren J, Ekman B, Andersson PO, Arnqvist HJ. Non-physiological levels of circulating cortisol in growth hormone-treated hypopituitary adults after conventional cortisone substitution.  Scand J Clin Lab Invest. 2004;  64 132-139
• 18 Jenkins JS, Sampson PA. Conversion of cortisone to cortisol and prednisone to prednisolone.  Br Med J. 1967;  2 205-207
• 19 Colburn WA, DiSanto AR, Stubbs SS, Monovich RE, DeSante KA. Pharmacokinetic interpretation of plasma cortisol and cortisone concentrations following a single oral administration of cortisone acetate to human subjects.  J Clin Pharmacol. 1980;  20 428-436
• 20 Srivastava LS, Werk Jr EE, Thrasher K, Sholiton LJ, Kozera R, Nolten W, Knowles HC, Jr. Plasma cortisone concentration as measured by radioimmunoassay.  J Clin Endocrinol Metab. 1973;  36 937-943
• 21 Turner AK, Carroll CJ, Pinkus JL, Charles D, Chattoraj SC. Simultaneous competitive protein binding assay for cortisol, cortisone, and prednisolone in plasma, and its clinical application.  Clin Chem. 1973;  19 731-736
• 22 Heazelwood VJ, Galligan JP, Cannell GR, Bochner F, Mortimer RH. Plasma cortisol delivery from oral cortisol and cortisone acetate: relative bioavailability.  Br J Clin Pharmacol. 1984;  17 55-59
• 23 Purnell JQ, Brandon DD, Isabelle LM, Loriaux DL, Samuels MH. Association of 24-h cortisol production rates, cortisol-binding globulin, and plasma-free cortisol levels with body composition, leptin levels, and aging in adult men and women.  J Clin Endocrinol Metab. 2004;  89 281-287
• 24 Mah PM, Jenkins RC, Rostami-Hodjegan A, Newell-Price J, Doane A, Ibbotson V, Tucker GT, Ross RJ. Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency.  Clin Endocrinol (Oxf). 2004;  61 367-375
• 25 Kivlighan KT, Granger DA, Schwartz EB, Nelson V, Curran M, Shirtcliff EA. Quantifying blood leakage into the oral mucosa and its effects on the measurement of cortisol, dehydroepiandrosterone, and testosterone in saliva.  Horm Behav. 2004;  46 39-46
• 26 Lovas K, Thorsen TE, Husebye ES. Saliva cortisol measurement: simple and reliable assessment of the glucocorticoid replacement therapy in Addison's disease.  J Endocrinol Invest. 2006;  29 727-731
• 27 Lovas K, Loge JH, Husebye ES. Subjective health status in Norwegian patients with Addison's disease.  Clin Endocrinol (Oxf). 2002;  56 581-588
• 28 Bergthorsdottir R, Leonsson-Zachrisson M, Oden A, Johannsson G. Premature mortality in patients with Addison's disease: a population-based study.  J Clin Endocrinol Metab. 2006;  91 4849-4853
• 29 Debono M, Ghobadi C, Rostami-Hodjegan A, Huatan H, Campbell MJ, Newell-Price J, Darzy K, Merke DP, Arlt W, Ross RJ. Modified-release hydrocortisone to provide circadian cortisol profiles.  J Clin Endocrinol Metab. 2009;  94 1548-1554
• 30 Johannsson G, Bergthorsdottir R, Nilsson A, Lennemas H, Hedner T, Skrtic S. Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study.  Eur J Endocrinol. 2009;  161 119-130

Correspondence